Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1428118-38-0Atorvastatin EP Impurity E (Na Salt)

● Auf Lager

Katalog-Nr.::	VE009244
CAS-Nr.::	1428118-38-0
Summenformel::	C33H34FN2NaO5
Molare Masse::	580.24 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1428118-38-0

Parent drug

Atorvastatin

IUPAC-Name

(3S, 5S)-7-[3-(Phenylcarbamoyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3, 5-dihydroxyheptanoic acid sodium salt

Synonyme

Atorvastatin Related Compound E/ ent-Atorvastatin/ (3S, 5S)-Atorvastatin (Na Salt)

SMILES

O=C([O-])C[C@@H](O)C[C@@H](O)CCN1C(C2=CC=C(F)C=C2)=C(C3=CC=CC=C3)C(C(NC4=CC=CC=C4)=O)=C1C(C)C.[Na+]

Beschreibung

Also known as Atorvastatin Related Compound E or ent-Atorvastatin or (3S, 5S)-Atorvastatin (Na Salt), it is one of impurity present in Atorvastatin, Atorvastatin is a competitive inhibitor of the enzyme HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver, where decreased hepatic cholesterol concentrations stimulate the upregulation of hepatic low-density lipoprotein receptors, which increases the hepatic uptake of LDL. Atorvastatin also reduces Very-Low-Density Lipoprotein-Cholesterol, serum triglycerides, and Intermediate Density Lipoproteins, but increases High-Density Lipoprotein Cholesterol. which is used to treat myocardial infarction and stroke.

References

McIver, L. A., & Siddique, M. S. (2022, September 2). Atorvastatin. Retrieved October 31, 2022, from Nih.gov website: https://www.ncbi.nlm.nih.gov/books/NBK430779/